SG11201608328RA - Method for predicting response to therapy for cancer - Google Patents
Method for predicting response to therapy for cancerInfo
- Publication number
- SG11201608328RA SG11201608328RA SG11201608328RA SG11201608328RA SG11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- therapy
- predicting response
- predicting
- response
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9015—Ligases (6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201608328RA SG11201608328RA (en) | 2014-04-24 | 2015-04-24 | Method for predicting response to therapy for cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201401785R | 2014-04-24 | ||
PCT/SG2015/050085 WO2015163826A1 (en) | 2014-04-24 | 2015-04-24 | Method for predicting response to therapy for cancer |
SG11201608328RA SG11201608328RA (en) | 2014-04-24 | 2015-04-24 | Method for predicting response to therapy for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201608328RA true SG11201608328RA (en) | 2016-11-29 |
Family
ID=54332870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201608328RA SG11201608328RA (en) | 2014-04-24 | 2015-04-24 | Method for predicting response to therapy for cancer |
Country Status (3)
Country | Link |
---|---|
US (1) | US20170045520A1 (en) |
SG (1) | SG11201608328RA (en) |
WO (1) | WO2015163826A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180209981A1 (en) * | 2015-07-23 | 2018-07-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976849A (en) * | 1998-02-05 | 1999-11-02 | Zeneca Limited | Human E3 ubiquitin protein ligase |
-
2015
- 2015-04-24 US US15/305,905 patent/US20170045520A1/en not_active Abandoned
- 2015-04-24 SG SG11201608328RA patent/SG11201608328RA/en unknown
- 2015-04-24 WO PCT/SG2015/050085 patent/WO2015163826A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20170045520A1 (en) | 2017-02-16 |
WO2015163826A1 (en) | 2015-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201702382B (en) | Combination therapy for cancer | |
IL304252A (en) | Method for treating cancer | |
IL289947A (en) | Method for treating cancer | |
FI3198035T3 (en) | Methods for predicting drug responsiveness | |
SG11201605585SA (en) | Targeted therapy for small cell lung cancer | |
GB201420859D0 (en) | Tumour analysis | |
GB201521357D0 (en) | Methods for predicting response to anti-TNF therapy | |
HK1231381A1 (en) | Combination therapy for cancer | |
EP2998732C0 (en) | Analysis method | |
IL246761A0 (en) | Combination therapy for cancer | |
IL251141B (en) | A method of predicting risk of recurrence of cancer | |
IL246558A0 (en) | Novel methods for treating cancer | |
SG11201609522TA (en) | Methods for treating cardiovascular diseases | |
PL3186332T3 (en) | Method for hydraulic fracturing | |
GB201420832D0 (en) | Location method | |
IL247270B (en) | Method of detecting cancer | |
EP3164122A4 (en) | Predicting response to cancer therapy | |
EP3121274A4 (en) | METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND | |
SG11201608328RA (en) | Method for predicting response to therapy for cancer | |
PL2985126T3 (en) | Method for edgebanding panels | |
GB201407837D0 (en) | Methods of cancer therapy | |
GB201411567D0 (en) | Quantification methods | |
AU2014902535A0 (en) | Predicting response to cancer therapy | |
GB201507268D0 (en) | Method for stimulating aerogenosis | |
GB201411884D0 (en) | Cancer therapy |